Immuno-Oncology | Specialty

Next Generation ALK Inhibitors for NSCLC

April 27th 2017

Treatment of ALK-Driven Refractory NSCLC

April 27th 2017

Sequencing Therapies in ALK+ NSCLC

April 27th 2017

Upfront Use of Second-Line Agents in ALK+ NSCLC

April 27th 2017

Treatment of Relapsed/Refractory ALK+ NSCLC

April 27th 2017

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

April 27th 2017

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

April 27th 2017

FDA Approval of Brigatinib for ALK+ NSCLC

April 27th 2017

Patterns of Progression on Crizotinib for ALK+ NSCLC

April 27th 2017

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

April 27th 2017

Biomarker Testing in NSCLC to Expand in Near Future

April 26th 2017

Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

April 26th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

April 26th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Expert Stresses Early Detection, Multidisciplinary Care for HCC

April 25th 2017

Amit Singal, MD, discusses the recent successes in the hepatocellular carcinoma treatment landscape and the challenges that still remain.

Expert Discusses Immunotherapy Advances in Head and Neck Cancer

April 25th 2017

Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.

Expert Highlights Novel Combos, Potential of Immunotherapy in MCL

April 25th 2017

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

April 25th 2017

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

April 25th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Immunotherapy Revolutionizes NSCLC, But Unanswered Questions Remain

April 25th 2017

Edward B. Garon, MD discusses the challenges researchers are currently facing with immunotherapy in NSCLC and what the future likely holds for the pivotal agents.

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.